Fispemifene

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Fispemifene
Fispemifene.svg
Clinical data
Synonyms HM-101
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
Formula C26H27ClO3
Molar mass 422.9493 g/mol
3D model (JSmol)

Fispemifene (INN, USAN) (developmental code name HM-101) is a nonsteroidal selective estrogen receptor modulator (SERM) of the triphenylethylene group that was developed for the treatment of male hypogonadism but was abandoned and never marketed.[1][2][3] It reached phase II clinical trials for this indication before development was terminated in March 2016.[1] The drug failed to achieve statistical significance on key effectiveness endpoints in clinical trials and was discontinued by its developer for strategic reasons.[1]

See also[edit]

References[edit]

  1. ^ a b c https://adisinsight.springer.com/drugs/800013715[permanent dead link]
  2. ^ Antonio Cano; Joacquim Calaf i Alsina; Jose Luis Duenas-Diez (22 September 2006). Selective Estrogen Receptor Modulators: A New Brand of Multitarget Drugs. Springer Science & Business Media. pp. 52–. ISBN 978-3-540-34742-2. 
  3. ^ Eckhard Ottow; Hilmar Weinmann (8 September 2008). Nuclear Receptors as Drug Targets. John Wiley & Sons. pp. 90–. ISBN 978-3-527-62330-3. 

External links[edit]